Previous studies have demonstrated that the therapeutic vaccine based on the enhancement of hepatitis B virus (HBV)-specific cytotoxic T lymphocyte (CTL) activity may lead to viral clearance in HBV-infected individuals. The endoplasmic reticulum (ER) chaperone Tapasin plays an important role in major histocompatibility complex (MHC) class I assembly and enhances specific MHC class Irestricted CTL activity by allowing more peptides to be translocated into the ER. Combining the specificity of hepatitis B core antigen (HBcAg) CTL epitope, the cell-penetrating property of cytoplasmic transduction peptide (CTP), and chaperone Tapasin may elicit robust specific HBV immune responses. In the present study, we confirmed the cytoplasmic localization preference of CTP-HBcAg 18 -27 -Tapasin fusion protein in vitro and evaluated the effects on promoting bone marrow-derived dendritic cells (BMDCs) maturation and enhancing T cells response to generate specific CTLs. Our results showed that CTP-HBcAg 18 -27 -Tapasin fusion protein could not only penetrate into the cytoplasm exactly and effectively to elevate Tapasin expression, but also increase the expression of surface molecules (CD80, CD83, CD86, and MHC-I) and secretion of cytokine (IL-12p70) of DCs. Moreover, DCs treated with the above fusion proteins increased significantly the cytokine secretion of proliferated T cells in vitro, the percentages of IFN-g 1
Introduction
Hepatitis B virus (HBV) infection remains a major public health problem worldwide. It is estimated that 350 million persons worldwide are chronically infected with HBV, and 600,000 deaths are attributed to acute or chronic HBV infection each year [1] . Interferon and nucleoside analogues have been widely used for the treatment of chronic HBV infection. However, these agents cannot attain complete eradication of the virus effectively and universally [2] . To our knowledge, chronic HBV-infected patients who tend to develop liver cirrhosis and hepatocellular carcinoma have a weaker immune response than patients with acute, selflimiting HBV infection [3] , and appropriate humoral and cellular immune responses are necessary for clearance of HBV infection [4] [5] [6] . Therefore, strategies to boost or broaden the weak virus-specific T-cell response of patients with chronic hepatitis B are proposed by means of various HBV vaccines.
Understanding how peptides are selected for presentation by major histocompatibility complex (MHC) class I is crucial to vaccination strategies based on cytotoxic T lymphocyte (CTL) priming. Tapasin is a class I-specialized molecule, whose requirement for antigen presentation is well documented [7] [8] [9] . It stabilizes transporter associated with antigen processing 1 (TAP1)/TAP2 heterodimers and facilitates peptide transport into the endoplasmic reticulum (ER) and bridges class I molecules to TAP [10] [11] [12] . Moreover, it facilitates loading of antigenic peptides and optimizes the peptide repertoire during this process [13, 14] . Recently, some studies have indicated that changes in Tapasin expression, as occurs with certain viruses and tumors, could alter dominance hierarchies and determine the success or failure of the immune response [15, 16] .
HBcAg 18 -27 epitope is a widely accepted CTL epitope and can stimulate CTL response against HBV infection [17] . DCs are regarded as the most efficient professional antigen-presenting cells (APCs), which are essential for the initiation of virus-specific T-cell responses. But the lipophilic nature of biological membranes of DCs restricts the direct intracellular delivery of proteins and peptides that are entering the cytoplasm and to be presented by MHC-I molecules. Cytoplasmic transduction peptide (CTP), which is a newly designed transduction peptide, is derived from the protein transduction domain (PTD) of HIV-1 TAT protein that carries molecules across the cell membrane with a preference to localize in the cytoplasmic compartment [18] . Therefore, as a biological tool, the properties of CTP may give an opportunity to the antigens and peptides of HBV, especially the HBcAg 18 -27 epitope, to enter the cytoplasm of DCs and to be presented by MHC-I molecules.
In this study, we tried to construct the prokaryotic expression vector for the CTP (GGRRARRRRRR)-HBcAg 18 -27 (FLPSDFFPSV)-Tapasin fusion protein and purify the protein by affinity chromatography. The membrane transduction potential and cytoplasmic localization preference of the CTP-HBcAg 18-27 -Tapasin fusion protein were evaluated in vitro. Our results demonstrated that chaperone molecular Tapasin modified intracellular HBcAg 18 -27 peptide to be presented by MHC-I molecules and promoted bone marrowderived dendritic cells (BMDCs) maturation to enhance HBV-specific CTL response efficiently.
Materials and Methods
Reagents and antibodies A pCMV-SPORT6 plasmid containing full-length of mouse Tapasin cDNA was purchased from Open Biosystems (Huntsville, USA). Anti-Tapasin antibody and anti-goat IgG secondary antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, USA). HBcAg 18 -27 epitope was synthesized by Sangon Biotech (Shanghai, China). The purity (.95%) of the peptide was confirmed by HPLC and mass spectrometry. Recombinant mouse granulocyte-macrophage colony-stimulating factor (rmGM-CSF) and interleukin-4 (rmIL-4) were purchased from Peprotech (London, UK). Phorbol 12-myristate 13-acetate (PMA), ionomycin and monensin, lipopolysaccharide (LPS) were obtained from Sigma (St Louis, USA). RPMI 1640 medium and fetal bovine serum (FBS) were purchased from Gibco (New York, USA). All of the fluorescent antibodies and isotype controls were purchased from eBioscience (San Diego, USA). Enzyme-linked immunosorbent assay (ELISA) kits for IL-12p70, IFN-g and IL-4 were purchased from R&D (Minneapolis, USA). Cell counting kit-8 (CCK-8) was purchased from Dojindo (Kumamoto, Japan). CytoTox 96 Non-Radioactive Cytotoxicity Assay kit was purchased from Promega (Madison, USA).
Animals and cell lines HLA-A2.1/K b transgenic mice, 6-8 weeks old, were purchased from the Jackson Laboratory (Bar Harbor, USA) and maintained in the experiment animal centre of Shanghai No. 6 Hospital under specific pathogen-free conditions. All experiments were approved by the Laboratory Animal Ethical Commission of Shanghai JiaoTong University. EL-4 cells (H-2K b , from ATCC) were cultured in Dulbecco's modified Eagle's medium containing 10% FBS at 378C under a humidified condition of 5% CO 2 and 100 U/ml penicillin. The 721.220 cell line (University of Wisconsin-Madison, USA) is a human Tapasin-deficient B lymphoblastoid cell line [19] . The cells were maintained at 378C with 5% CO 2 in RPMI 1640 medium supplemented with 10% FBS, and 300 mg/ml G418.
Vectors construction
A cDNA sequence encoding the whole open reading frame of the mouse Tapasin protein was generated by a polymerase chain reaction (PCR) strategy from the pCMV-SPORT6 plasmid containing the complete Tapasin genes. A 5 0 primer containing the BamHI and a 3 0 primer containing the EcoRI site were used to generate a 1476-bp PCR product. Sequences of the paired primers used for PCR amplification were presented as follows:
0 -aaagaattcttattactgtgacttctttga-3 0 (reverse). Underlined nucleotides represented the BamHI and EcoRI sites, respectively. After being subcloned and completely sequenced to verify the correct reading frame and absence of mutations, the CTP-HBcAg 18 -27 -Tapasin genes were inserted into the unique BamHI to EcoRI site of the prokaryotic pREST-B expression vector (Invitrogen, Carlsbad, USA) and to get pREST-B-CTP-HBcAg 18 -27 -Tapasin plasmid [ Fig. 1(A) ]. Furthermore, the objective plasmid was identified by restriction enzyme digestions, colony PCR, and bidirectional DNA sequencing. Based on the pREST-B-CTP-HBcAg 18-27 -Tapasin plasmid, the paired primers used for PCR amplification of control genes (CTP-HBcAg [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] and HBcAg 18 -27 -Tapasin) were 5 0 -tttggatccatttctgccgagcgatttt-3 0 (forward), 5 0 -aaagaattcbttattacacgctcggaaaa-3 0 (reverse) and 5 0 -tttggatcc aggcggccgtcgtgcgcgt-3 0 (forward), 5 0 -aaagaattcbttattacac gctcggaaaa-3 0 (reverse), respectively. Because of the CTP-HBcAg 18 -27 fusion protein including small amount of nucleotides, GST-tag was used to express and purify the protein finally. The PCR products of control genes (CTP-HBcAg 18 -27 and HBcAg 18 -27 -Tapasin) were recycled, purified, and cloned into pGEX-6p-1 (GE Healthcare, Buckinghamshire, UK) or pREST-B vectors, respectively, and the above plasmids were identified by enzyme cutting and sequencing.
Protein expression, purification, and western blot analysis The host Escherichia coli BL21 (DE3) cells were transformed with constructed vectors, and harvested and then lysed by sonication. After centrifugation, the supernatants containing fusion proteins (CTP-HBcAg 18 -27 -Tapasin and HBcAg 18 -27 -Tapasin) were purified by Ni 2þ -chelating column. Purified fusion proteins were analyzed by western blot, subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred onto a nitrocellulose membrane. The membrane was incubated with anti-Tapasin monoclonal antibody, followed by horseradish peroxidase-conjugated anti-goat antibody. The fusion proteins were cleaved by recombinant enterokinase (Invitrogen) according to the manufacturer's instructions to remove His-tag from the recombinant proteins ultimately. Meanwhile, the control CTP-HBcAg 18 -27 protein was expressed and purified according to the manufacturer's instructions of pGEX-6p-1 expression vector and separated from GST-tag using PreScission Protease (GE Healthcare). The above target proteins were dissolved into doubledistilled water and had undetectable endotoxin and salts level after being eluted by ActiClean Etox Prepacked Column (Sterogene Bioseparations Inc., Carlsbad, USA) and Zeba Spin Desalting Column (Pierce Biotechnology, Rockford, USA), respectively. All proteins were stored at 48C until use.
DCs isolation, treatment, and phenotypic analysis DCs were generated from bone marrow cells collected from the femurs and tibiae of HLA-A2.1/K b transgenic mice according to a published method with some modifications [20] . In brief, bone marrow cells from the femurs and tibiae of mice were cultured in complete RPMI 1640 culture medium supplemented with rmGM-CSF (20 ng/ml) and rmIL-4 (10 ng/ml). After 2-day incubation, the nonadherent single cells were gently removed, and new medium supplemented with rmGM-CSF and rmIL-4 at the concentration previously described was added. On Day 5, these cells were cultured for an additional 72 h in the presence of CTP-HBcAg 18 -27 -Tapasin (20 mg/ml), CTPHBcAg 18 -27 (20 mg/ml), HBcAg 18 -27 -Tapasin (20 mg/ml), and HBcAg 18-27 (20 mg/ml) in addition to rmGM-CSF, rmIL-4, and LPS (20 ng/ml). On Day 8, non-adherent and loosely adherent cells were harvested as DCs. The morphology of DCs was observed by transmission and scanning electron microscopy. The electron microscopy samples of DCs were treated using the standard experiment method. The expression of DCs surface molecules was analyzed by incubation with FITC-labeled rat anti-mouse McAbs against CD11c and PE-labeled rat anti-mouse monoclonal antibody (McAb) against MHC-I, CD80, CD83, and CD86. Fluorescence analyses were performed on COULTER EPICS XL Flow Cytometer (Beckman, Miami, USA) using Expo32-ADC software (Beckman). Intracellular localization analysis by immunofluorescent staining and western blotting BMDCs and 721.220 cells (5 Â 10 4 cells/well) were cocultured with 20 mg/ml recombinant proteins CTP-HBcAg 18 -27 -Tapasin, HBcAg 18 -27 -Tapasin and negative control (medium), respectively. After incubated with antigens for 24 h, cells were washed with PBS, and fixed in cold methyl alcohol and permeabilized in 0.1% Triton X-100. Non-specific epitopes were blocked by using BSA and then cells were incubated with anti-Tapasin McAb. After washing, the FITC labeled anti-mouse IgG secondary antibody was added and after being incubated for 60 min, the above cells were stained with DAPI or PI for 3 min, respectively. The cells were detected by LSM 510 Laser Scanning Confocal Microscope (Zeiss, Oberkochen, Germany) and analyzed by LSM Image Examiner Software (Zeiss). The mean fluorescence intensity (MFI) of the entire field of view was calculated in five sites from four corners to the center of each section.
After incubation with above stimulus for 24 h, DCs were harvested to analyze the expression of Tapasin by western blotting. Anti-Tapasin McAb was used as the primary antibody, and horseradish peroxidase-conjugated rabbit antigoat IgG was used as the secondary antibody.
IL-12p70 assay and splenocyte proliferation assay Immature DCs (Day 5) were treated by the indicated antigens for 72 h and the levels of IL-12p70 in harvested supernatants of mature DCs (Day 8) were measured by using a standard sandwich ELISA kit (R&D) according to the manufacturer's instructions. The cytokine concentrations were calculated by appropriate standard curves. On Day 8, DCs were harvested and pretreated with 25 mg/ml mitomycin C for 30 min at 378C in an atmosphere of 5% CO 2 . T cells derived from splenocytes were isolated by nylon wool columns and plated in 96-well plates as responder cells (5 Â 10 5 cells/well), and then were cocultured with mature DCs at various responder/stimulator ratios (5 : 1, 10 : 1, or 20 : 1). The cells were incubated in a final volume of 200 ml of complete RPMI 1640 for 72 h, and 10 ml CCK-8 solution was added to the plates for 4 h at 378C. The absorbance was finally read at 450 nm.
Measurement of cytokine secretion and analysis of intracellular cytokine of proliferative T cells
The above T cells stimulated by DCs were cultured for 6 days in the presence of 25 IU/ml of IL-2. The supernatants were harvested and the presence of IFN-g and IL-4 were detected by commercial mouse cytokine immunoassay ELISA kits according to the manufacturer's instructions. The concentrations of cytokines in the samples were determined from the standard curves and are expressed as pg/ml. Cells staining and flow cytometry were performed according to protocols provided by the manufacturers. In brief, the above proliferative T cells (cultured for 6 days) at 10 : 1 of T cells/DC ratio were suspended in complete RPMI 1640, and stimulated for 6 h in the presence of 25 mg/ml of PMA, 1 mg/ml of ionomycin and 1.7 mg/ml of monensin. After washes with PBS, cells were stained with saturating concentrations of phycoerythrin (PE)-conjugated anti-CD8a McAb. After fixed with Fix and Perm reagent A and B, the cells were incubated for 20 min with FITC-labeled anti-IFN-g McAb, followed by washing twice with PBS and analyzing by FACS.
CTL assay EL-4 cell pulsed with 10 mg/ml HBcAg 18 -27 was used as target cells, and EL-4 cell alone was used as controls [21] . 
Statistical analysis
Data are expressed as the mean + SD. Statistical analyses of data were performed using SPSS software. Statistical comparison was made using analysis of variance (ANOVA). A value of P , 0.05 was considered significant statistically.
Results
Construction of expression vectors and purification and western blot analysis of fusion proteins As shown in Fig. 1(B) , the CTP-HBcAg 18 -27 -Tapasin gene was 1476-bp in size by PCR amplified from the plasmid of pCMV-SPORT6, and the genes of CTP-HBcAg 18-27 and HBcAg 18 -27 -Tapasin were 75-bp and 1443-bp, respectively. Furthermore, both the target prokaryotic expression plasmid pREST-B-CTP-HBcAg 18 -27 -Tapasin and two control plasmids were successfully constructed and identified by restriction enzyme digestion and complete sequencing (data not shown).
The fusion proteins were induced by IPTG and purified by Ni 2þ -chelating column or Gluthatione Sepharose column, expressed at a high solubility level in the lysed supernatants, and the purified fusion proteins were found to be nearly 85% purity by SDS -PAGE analysis [ Fig. 1(C) ]. Ultrasonically lysed and purified products were further confirmed by western blot analysis using mouse anti-Tapasin antibody or anti-GST antibody [ Fig. 1(D) ].
Tapasin enhances cytotoxic T lymphocyte activity CTP-HBcAg 18 -27 -Tapasin induced DCs differentiation and maturation At the end of the treatment, the amount of BMDCs (CD11c) was 80% by FACS analysis. The morphological characteristic of mature BMDCs showed increased ruffles and rough lames on cell surfaces by scanning electron microscopy and larger nuclei with a thick rim of heterochromatin, numerous mitochondria, more lysosomes and ribosomes, rough ER, and Golgi body by transmission electron microscopy [ Fig. 2(A) ]. To examine the phenotypic changes on DCs induced by fusion proteins, the expression levels of MHC-I, CD80, CD83, and CD86 were further analyzed by flow cytometry. As shown in Fig. 2(B,C) , the percentages of MHC-I, CD80, CD83, and CD86 on DCs induced by CTP-HBcAg 18 -27 -Tapasin were significantly increased than other groups.
Cytoplasmic localization of CTP-HBcAg 18 -27 -Tapasin fusion protein
Recombinant proteins were added into 721.220 cells to determine whether the recombinant of CTP affected the cellular uptake of the Tapasin protein. To further characterize its intracellular localization after transduction, immunofluorescent staining and confocal microscopy were used. As shown in Fig. 3(A) , Tapasin protein could be expressed in the cytoplasm of 721.220 cells as indicated by the green fluorescence mainly detected in the cytoplasm. Also, it was clearly distinct from the nucleus-specific DAPI signal (blue) observed on the merged confocal microscopic images. While on the contrary, there was no green fluorescence in the cytoplasm of the cells treated with HBcAg 18 -27 -Tapasin fusion protein, demonstrating the inability of the HBcAg 18 -27 -Tapasin fusion protein to penetrate the cell membrane without the mediation of the CTP peptide. In addition, the potent transduction potential and the cytoplasmic localization of CTP-HBcAg 18 -27 -Tapasin fusion protein were confirmed in DCs [ Fig. 3(B) ]. Moreover, the mean fluorescence intensity in the DCs cocultured with CTP-HBcAg 18 -27 -Tapasin was much higher than others [ Fig. 3(C) ]. Furthermore, the expression of Tapasin in different groups was detected by western blotting to confirm the transduction ability of fusion proteins indirectly. The result showed that the expression level of Tapasin protein in CTP-HBcAg 18 -27 -Tapasin group was significantly higher than those of others [ Fig. 3(D) ].
CTP-HBcAg 18-27 -Tapasin increased IL-12p70 production and enhanced T-cell proliferation Based on the fact that IL-12 is known to induce T-cell proliferation and is the only vital cytokine produced by DCs, we examined the effect of fusion proteins on the production of IL-12p70. As shown in Fig. 4(A) , higher IL-12p70 (60.46 + 9.10 pg/ml) production was found in the supernatant of DCs treated by CTP-HBcAg 18 -27 -Tapasin. However, the levels of IL-12p70 had no significant difference between CTP-HBcAg 18 -27 The results showed that the T-cell proliferation capacities of DCs pulsed with CTP-HBcAg 18-27 -Tapasin were much higher than others [ Fig. 4(B) ].
CTP-HBcAg 18 -27 -Tapasin boosted cytokine release and the frequency of specific CD81 T cells elicited from proliferative T cells in vitro
The functional capacity of proliferative T cells was analyzed by their cytokine release in response to different fusion proteins. As shown in Fig. 5(A) , T cells stimulated by CTP-HBcAg 18 -27 -Tapasin produced a higher level of IFN-g compared with the CTP-HBcAg 18 -27 group. However, the level of IL-4 had no significant difference between HBcAg 18 -27 -Tapasin and CTP-HBcAg 18 -27 -Tapasin groups.
We then measured the intracellular levels of IFN-g in single cell by flow cytometry. The number of doubly stained positive cells was counted by flow cytometry after incubation. As shown in Fig. 5(C) , the percentage of specific IFN-g þ CD8 þ T cells induced by mature DCs treated with CTP-HBcAg 18 -27 -Tapasin fusion protein was significantly higher than other groups. These data demonstrated that Tapasin modified intracellular CTL epitopes to enhance the generation of specific CTLs.
CTP-HBcAg 18 -27 -Tapasin induced CTLs
To evaluate the specific cytotoxicity of T lymphocytes in the various groups, murine BMDCs pulsed with different antigen-stimulated T cells against EL-4 cells were treated by HBcAg 18 -27 . We used LDH release assay to verify CTL killing response, and the results of HBcAg-specific CTL killing activity were shown in Fig. 6 . Results showed that CTP-HBcAg 18 -27 -Tapasin induced effective CTL activity higher than the controls groups. Meanwhile, specific T lymphocytes induced by different stimuli were non-specific cytotoxic to EL-4 cells which were unrelated target cells (data not shown). These results suggest that CTPHBcAg 18 -27 -Tapasin induces specific CTL activities, which is consistent with the high level of IFN-g expressed in CD8 þ T cells.
Discussion
It is well known that one central goal of the current immunotherapy and vaccine development is to facilitate antigen presentation to induce robust immune responses. Recent studies have demonstrated that CTLs play a critical role in the control and termination of HBV infection. CTLs can eliminate HBV by killing infected hepatocytes and secreting antiviral cytokines. Acutely infected patients characteristically elicit a vigorous, polyclonal, and multi-specific CTL response that is usually sufficient to clear the infection, while persistently infected patients elicit weak or undetectable HBV-specific CTL responses [6] . Therefore, the therapeutic vaccine based on enhancement of HBV-specific CTL may lead to viral clearance in chronically infected individuals. CTLs are activated by the presentation to T-cell receptors of short peptides (usually derived from endogenous, cytosolic antigens), and associated with MHC class I molecules. It is thus generally considered that the induction of specific CTL responses against an antigen requires its synthesis or transport by an appropriate vector into the cytoplasm of APCs. As a result of the recent notable progress in the understanding of the mechanisms of antigen presentation and activation of T-cell responses, some systems have been developed to enable such antigen delivery into the 'classical' endogenous MHC class I pathway. DCs are now well recognized as the most potent professional APCs, with a unique capacity to interact with naive T cells to initiate primary immune responses. Thus, targeting DCs could represent the main objective in designing new delivery systems for vaccine development.
Discovery of the PTD of HIV-Tat has opened avenues for directing in vitro and in vivo delivery of proteins into cells. Recently, some researchers have demonstrated that DCs pulsed with PTD fusion proteins were effective on eliciting potent virus or tumor-specific CTL responses against virus or tumor [22] . Although the mechanism for internalization and processing of PTD-containing antigen by DC has not yet been clarified, these data suggested that fusion protein could transduce DC efficiently, prolong processing by proteasomes for MHC class I restricted to CTLs, and induce specific immunity. Meanwhile, our previous results showed that recombinant PTD-HBcAg could penetrate into DCs cytoplasm and efficiently elicited HBV-specific CTLs to inhibit HBV replication in transgenic mice [23] . However, the majority of PTD and PTD-conjugated molecules translocate to the nucleus rather than to the cytoplasm after transduction. Latest reports have testified that CTP ensure the efficient cytoplasmic delivery of the CTP-fused biomolecules. In comparison with PTD, CTP and its fusion partners exhibited a clear preference for cytoplasmic localization, and also markedly enhanced membrane transduction potential [24] . In the present study, to enhance antigen Tapasin enhances cytotoxic T lymphocyte activity peptides entry into cells, we constructed the prokaryotic expression vector for CTP-HBcAg 18 -27 -Tapasin fusion protein and successfully purified the fusion protein. CTP-HBcAg 18 -27 -Tapasin was assessed by confocal microscopy, in an attempt to characterize their intracellular localization after transduction. As shown in Fig. 3(A,B) , the above fusion protein remained primarily in the cytoplasm of 721.220 cells and DCs after transduction. Furthermore, in order to detect the transduction ability of CTP-HBcAg 18 -27 -Tapasin, we quantified the intracellular Tapasin expression by western blotting. The results showed that the amount of protein expression in CTP-HBcAg 18-27 -Tapasin groups was much higher than in control groups. Therefore, the target antigens were transported efficiently and exactly into the cytoplasm of DCs via CTP. Based on the property of CTP, it was assured to further verify the immunogenicity of soluble fusion proteins on eliciting specific CTL activity.
During the assembly of the MHC class I molecules with peptides in the peptide-loading complex, a series of transient interactions are made with ER-resident chaperones. These interactions culminate in the trafficking of the MHC class I molecules to the cell surface and presentation of peptides to CTLs. Within the peptide-loading complex, the glycoprotein Tapasin exhibits a relevant function. For many human and mouse class I allotypes, Tapasin increases cell surface class I molecule expression. Tapasin stabilizes TAP, and increases steady-state levels of TAP, thereby allowing more peptides to be translocated into the ER. Tapasin also allows a physical link between class I and the TAP, and by doing so, may increase the effective concentration of peptides that are available for class I binding [25] . Moreover, later findings indicated that the C-terminus of Tapasin played a vital role in enabling MHC class I molecules to be expressed at the surface of cells [26] . Some reports implicated that Tapasin had a close association with some tumors, virus infection and autoimmune diseases mainly by the reason that lacking Tapasin influenced the effective antigen presentation of APC [27, 28] . Some researchers used a DNA vaccine encoding the ER chaperone molecule linked to HPV-16 E7 antigen to significantly enhance E7 DNA vaccine potency by generating strong E7-specific CD8 þ T cell-mediated immune responses as well as strong anti-tumor effect against E7-expressing tumors in vaccinated mice [16] . The linkage of the chaperone molecule to E7 may facilitate the transportation of E7 into the ER and increase MHC class I presentation of E7 because of these molecules containing an N-terminal ER signal sequence. Recent studies have demonstrated that target antigen to the ER may lead to enhance specific MHC class I-restricted CTL activity [29] . Our data demonstrated that the incorporation of Tapasin with HBcAg 18 -27 may facilitate the transportation of CTL peptides into the ER and increase MHC class I presentation of target peptides. In our study, the BMDCs were stimulated by CTP-HBcAg 18 -27 -Tapasin fusion protein that had higher levels of expression of co-stimulatory molecules (MHC-I, CD80, CD83, and CD86) and cytokine production, including IL-12p70, in comparison with the control proteins. There were massive virus antigens in the cytoplasm of DCs with the delivery of CTP. Moreover, the modification of Tapasin increased MHC-I expression and facilitated to present antigen peptides to CD8 þ T cells.
IL-12p70 secreted by mature DC skews the effector response towards Th1-type and recruits memory T cells and NK cells [30] . So, we detected IL-12p70 production of DCs into culture medium after addition of different maturation factors. As expected, IL-12p70 production of DCs induced by CTP-HBcAg 18 -27 -Tapasin was markedly elevated among different treatments. The morphology of mature DCs was observed by electron microscopy and there were numerous mitochondria, more lysosomes and ribosomes, rough ER, and Golgi body in DCs pulsed with CTP-HBcAg 18 -27 -Tapasin. As we know, Th1 and Tc1 cells primarily secrete type I cytokines (IL-2, IFN-g), whereas Th2 and Tc2 cells secrete type 2 cytokines (IL-4, IL-10). The Th1/Tc1 circuit appears to be crucial for the induction of CTL with killing activity, which is beneficial for viral or tumor eradication [31] . In our study, the Th1-type cytokine (IFN-g) secretion of proliferated T cells was increased significantly in the experimental group compared with other controls. However, there was no significant difference in the secretion of Th2-type cytokine (IL-4) between each group. The results indicated that DCs by pulsed CTP-HBcAg 18 -27 -Tapasin could promote Th1 polarization and activate cell-mediated immunity efficiently. Furthermore, DCs pulsed with CTP-HBcAg 18 -27 -Tapasin could induce more IFN-g þ CD8 þ T cells and robust specific CTL activity than DCs pulsed with the controls. The specific cytotoxic activity of proliferated Tc1 cells against EL-4 cells pulsed with CTL antigens confirmed the effect of CTP-HBcAg 18 -27 -Tapasin on enhancing specific CTL response. The results showed that CTP-HBcAg 18 -27 -Tapasin could enhance the capacity of T cells proliferation, cytokines release, and CTLs generation in vitro.
In conclusion, our study demonstrated that the modification of Tapasin can enhance the presentation of target antigens via intracellular delivery to DCs and elicit antigenspecific CTL immune responses efficiently. Therefore, antigen peptide linked to chaperone Tapasin may offer a new strategy to the development of HBV vaccines in future.
